{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:59:17Z","timestamp":1790287157229,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jfo.2026.104981","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:54:16Z","timestamp":1790279656000},"page":"104981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recommandations pratiques de la F\u00e9d\u00e9ration France Macula sur l\u2019utilisation des biosimilaires des anti-VEGF"],"prefix":"10.1016","volume":"49","author":[{"given":"D.","family":"El Ghazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Srour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Oubraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.F.","family":"Korobelnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Kodjikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Semoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.Y.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Amoroso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.J.","family":"Mehanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Miere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Souied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2026.104981_bib0090","series-title":"Rapport annuel sur l\u2019\u00e9volution des charges et des produits","article-title":"Am\u00e9liorer la qualit\u00e9 du syst\u00e8me de sant\u00e9 et ma\u00eetriser les d\u00e9penses\u202f: propositions pour l\u2019ann\u00e9e 2026","year":"2025"},{"key":"10.1016\/j.jfo.2026.104981_bib0095","series-title":"Les m\u00e9dicaments biosimilaires dans l\u2019UE Guide d\u2019information destin\u00e9 aux professionnels de la sant\u00e9","year":"2019"},{"key":"10.1016\/j.jfo.2026.104981_bib0100","unstructured":"Groupement pour l\u2019\u00e9laboration et la r\u00e9alisation de statistiques (GERS). Donn\u00e9es de p\u00e9n\u00e9tration des biosimilaires anti-VEGF en France. Mars et mai 2026."},{"key":"10.1016\/j.jfo.2026.104981_bib0105","unstructured":"Lois de financement de la S\u00e9curit\u00e9 sociale 2014, 2017, 2020, 2022, 2024, 2025, 2026 (Journal Officiel de la R\u00e9publique Fran\u00e7aise). Code de la sant\u00e9 publique, articles L. 5125-23-1\u00a0et suivants."},{"key":"10.1016\/j.jfo.2026.104981_bib0110","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2165\/00003495-200767080-00007","article-title":"Ranibizumab","volume":"67","author":"Blick","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.jfo.2026.104981_bib0115","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s11912-013-0368-7","article-title":"Aflibercept--a decoy VEGF receptor","volume":"16","author":"Ciombor","year":"2014","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jfo.2026.104981_bib0120","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ophtha.2021.04.031","article-title":"Efficacy and safety of biosimilar FYB201\u00a0compared with ranibizumab in neovascular age-related macular degeneration","volume":"129","author":"Holz","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2026.104981_bib0125","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1136\/bjophthalmol-2021-319637","article-title":"Biosimilar SB11\u00a0versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes","volume":"107","author":"Bressler","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2026.104981_bib0130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/jamaophthalmol.2022.5403","article-title":"Immunogenicity with ranibizumab biosimilar SB11 (Byooviz) and reference product lucentis and association with efficacy, safety, and pharmacokinetics: a post hoc analysis of a phase 3\u00a0randomized clinical trial","volume":"141","author":"Bressler","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.jfo.2026.104981_bib0135","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1097\/IAE.0000000000004174","article-title":"Efficacy and safety of the proposed biosimilar aflibercept SDZ-AFL in patients with neovascular age-related macular degeneration: 52-week results from the phase 3\u00a0Mylight study","volume":"44","author":"Bordon","year":"2024","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2026.104981_bib0140","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1038\/s41433-025-04030-7","article-title":"FYB-201 biosimilar ranibizumab (Ongavia\/Ranivisio\/Cimerli) efficacy and safety in clinical settings FORCE study","volume":"39","author":"Sharma","year":"2025","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jfo.2026.104981_bib0145","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/s41433-025-03813-2","article-title":"Aflibercept 2\u00a0mg biosimilar (Tyalia) real-world experience from Iran: ATRIA study","volume":"39","author":"Avadzadeh","year":"2025","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jfo.2026.104981_bib0150","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jfo.2016.12.003","article-title":"Prise en charge individualis\u00e9e des patients atteints de DMLA exsudative, le protocole IOI\u00a0: injection \u2013\u00a0observation\u00a0\u2013 individualisation [Individualized management of patients with exudative AMD, IOI protocol: injection-observational-individualization]","volume":"40","author":"Semoun","year":"2017","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jfo.2026.104981_bib0155","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/IAE.0b013e318227aa09","article-title":"Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization","volume":"32","author":"Yoon","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2026.104981_bib0160","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1177\/24741264231202080","article-title":"Biosimilar to biosimilar anti-VEGF switching for retinal diseases","volume":"7","author":"Sharma","year":"2023","journal-title":"J Vitreoretin Dis"},{"key":"10.1016\/j.jfo.2026.104981_bib0165","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s40123-024-01002-0","article-title":"Clinical outcomes and experiences with prefilled syringes versus vials for intravitreal administration of anti-VEGF treatments: a systematic review","volume":"13","author":"Uzzan","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jfo.2026.104981_bib0085","first-page":"CD015804","article-title":"Anti-vascular endothelial growth factor biosimilars for neovascular age-related macular degeneration","volume":"6","author":"Sunaga","year":"2024","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S018155122600207X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S018155122600207X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:03:17Z","timestamp":1790283797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S018155122600207X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S018155122600207X"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2026.104981","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recommandations pratiques de la F\u00e9d\u00e9ration France Macula sur l\u2019utilisation des biosimilaires des anti-VEGF","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2026.104981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104981"}}